Reason for Submitting the Extraordinary Report The Company has submitted the Extraordinary Report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of
Wednesday, December 18, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Takeda Pharmaceutical Company Limited has submitted an Extraordinary Report regarding the dissolution of its subsidiary, Shire Pharmaceuticals International Unlimited Company, as part of a merger restructuring. This decision, resolved on September 25, 2024, will result in Shire being liquidated. The company will initiate the administrative and legal processes for liquidation in compliance with local regulations, although a completion date remains unknown. This merger and subsequent dissolution represent significant changes within Takeda's structure.
Price reaction · baseline $13.36 (2024-12-17 close) · hit after-hours · clean, no other TAK news in the window
day 0 close · peak
-1.9%
Market Sentiment Analysis
CONCERNS & RISKS
The decision to dissolve Shire Pharmaceuticals International Unlimited Company may impact business operations and financial stability.
The liquidation process introduces uncertainty regarding the completion timeline.
Shareholder confidence could be affected due to the significant restructuring involved.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
TAK-559
Phase 3 · Diabetes Mellitus
Full Press Release Details
Amendment Extraordinary Report
Cover
Document Filed
Extraordinary Report (Inline XBRL attached to the Amendment Extraordinary Report dated December 18, 2024)
Filed with
Director, Kanto Local Finance Bureau
Filing Date
September 26, 2024
Company Name
Takeda Pharmaceutical Company Limited
Title and Name of Representative
Christophe Weber, Representative Director, President Chief Executive Officer
Address of Head Office
1-1, Doshomachi 4-chome, Chuo-ku, Osaka (The above address is the registered head office location and the ordinary business operations are conducted at the "Nearest Place of Contact")
Telephone Number
Not applicable
Name of Contact Person
Not applicable
Nearest Place of Contact
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo (Global Headquarters)
Telephone Number
+81-3-3278-2111 (Main telephone number)
Name of Contact Person
Norimasa Takeda, Head of Global Consolidation and Japan Reporting, Global Finance
Please for public inspection
Takeda Pharmaceutical Company Limited (Global Headquarters) (1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo) Tokyo Stock Exchange, Inc. (2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo) Nagoya Stock Exchange, Inc. (8-20, Sakae 3-chome, Naka-ku, Nagoya) Fukuoka Stock Exchange (14-2, Tenjin 2-chome, Chuo-ku, Fukuoka) Sapporo Stock Exchange (14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo)
1.
Reason for Submitting the Extraordinary Report
The Company has submitted the Extraordinary Report pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Law and Article 19, Paragraph 2, Item 3 of the Cabinet Office Ordinance concerning Disclosure of Corporate Affairs, etc. to report on resolution dated September 25, 2024, on a merger between specified subsidiaries that results in change to a status of the below specified subsidiary, and on the procedural changes related to this change of the specified subsidiary, resolved on December 17, 2024.
2.
Details of the Extraordinary Report
(1)
Outline of specified subsidiaries
(a)
Company name
Shire Pharmaceuticals International Unlimited Company
(b)
Headquarters
Block 2, Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, D02 HW68 Republic of Ireland
(c)
Name of representatives
Denis Anthony Ahern, Fiona Foley, Barbara Lenzlinger, Susan O'Reilly
(d)
Capital
USD 6,891,886,042
(e)
Description of business
Shareholding of former Shire group entities
(2)
Number of votes held prior to and after merger
(a)
Number of votes
Before merger
6,891,886,042 votes (of which 6,891,886,042 votes owned indirectly)
After merger
0 votes
(b)
Voting rights ownership ratio
Before merger
100.0 % (of which 100.0 % owned indirectly)
After merger
0.0%
(3)
Reason for change and date of liquidation
(a)
Reason for change
The Company has decided to dissolve Shire Pharmaceuticals International Unlimited Company, which is a specified subsidiary, through liquidation.
(b)
Date of liquidation
The administrative and legal processes of the liquidation will commence in due course in compliance with local regulations, however, the date of completion cannot be determined yet.
Frequently Asked Questions
What is the purpose of the submitted Extraordinary Report?
The report details a merger between subsidiary companies and changes in their statuses, as required by Japanese financial laws.
Who are the representatives of Shire Pharmaceuticals?
The representatives include Denis Anthony Ahern, Fiona Foley, Barbara Lenzlinger, and Susan O'Reilly.
What is the capital of Shire Pharmaceuticals?
Shire Pharmaceuticals has a capital of USD 6,891,886,042.
What will happen to Shire Pharmaceuticals after the merger?
Shire Pharmaceuticals International Unlimited Company will be dissolved through liquidation.
When will the liquidation of Shire Pharmaceuticals be completed?
The completion date of the liquidation is uncertain and will depend on local regulations.